Printer Friendly

U.S. PATENT AND TRADEMARK OFFICE RULES IN FAVOR OF SCIOS NOVA'S FIBROBLAST GROWTH FACTOR

 MOUNTAIN VIEW, Calif., Nov. 1 /PRNewswire/ -- Scios Nova Inc. (NASDAQ: SCIO) today announced that the United States Patent and Trademark Office (PTO) has ruled in its favor in a patent interference relating to the recombinanat production of human basic fibroblast growth factor (bFGF).
 In a decision issued by the Board of Appeals and Interferences, the PTO ruled that Scios Nova was entitled to a patent containing claims covering DNA molecules which encode human bFGF; expression vectors containing the DNA; transformed cells or microorganisms containing the expression vectors; and the method of producing human bFGF by recombinant expression.
 The decision culminated an interference proceeding between Scios Nova Inc. and the Salk Institute for Biological Studies which began in August 1989. An interference is a proceeding in the PTO to determine who, among two or more parties claiming the same invention, is entitled to a patent. Scios Nova's application involved in the interference was based on the work of scientists John Fiddes and Judith Abraham in the isolation and cloning of DNA sequences encoding human bFGF. Salk's application was based on the isolation and sequencing of bovine bFGF protein. Both parties had asserted a right to patent claims which encompassed the human DNA sequence.
 Relying on several recently issued decisions of the United States Court of Appeals for the Federal Circuit, the Board of Appeals and Interferences ruled that Scios Nova's work on the human DNA sequences was patentably distinct from Salk's work on the bovine protein. As a result, Salk is entitled only to DNA sequences encoding the bovine protein, whereas Scios Nova is entitled to a patent containing claims to the human sequences. The Salk Institute may appeal the decision of the PTO in the federal courts.
 Basic fibroblast growth factor is a protein naturally produced by the body, which stimulates the growth of many different cell types that are key to the healing response following injury. Scios Nova is conducting Phase II studies using bFGF to treat two types of soft tissue wounds. As recently announced, upon completion of the Phase II studies in late 1993 or early 1994, the company plans to secure a partner to fund further development and commercialization of bFGF in the United States.
 "We are gratified that the Patent and Trademark Office has confirmed what the scientific community has long recognized, that scientists at Scios Nova were the first to clone human basic firbroblast growth factor," said Peter R. Shearer, Scios Nova chief patent counsel.
 Scios Nova, based in Mountain View, is a biopharmaceutical company engaged in the discovery, development and commercialization of novel human therapeutics. Scios Nova focuses its research and development efforts toward the treatment of acute illnesses, primarily in the areas of cardio-renal disease and inflammation. The company is also collaborating with corporate partners in the areas of fibroblast growth factor (bFGF), insulinotropin and Alzheimer's disease. The company's drug discovery technology encompasses both biotechnology techniques and small molecule design to develop new biopharmaceutical products.
 -0- 11/1/93
 /CONTACT: Kira Bacon of Scios Nova Inc., 415-940-6629/
 (SCIO)


CO: Scios Nova Inc. ST: California IN: MTC SU:

TB-TM -- SJ006 -- 8958 11/01/93 08:30 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 1, 1993
Words:524
Previous Article:MERGER OF TWO WORLDWIDE GROUPS MAKES WNI LEADER IN THE $1 BILLION WEATHER SERVICES MARKET
Next Article:FDIC APPROVES MID-STATE MERGER INTO AMSOUTH BANK OF FLORIDA
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters